Additionally, in young overweight patients with IR and PCOS, a 12-month regimen of metformin therapy demonstrated a significant reduction in the prevalence of MS and amelioration of liver complications, enhancing insulin sensitivity (Hu et al., 2021). This evidence concerns the gene INS and polycystic ovary syndrome.